Category Archives: TRIPS plus

Canadian generic drugmakers find fault with USMCA

Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, USMCA | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

WIPO: Proposal to amend PCT Regulations undermines TRIPS flexibilities

Geneva, 15 June (TWN) – A proposal to amend a treaty regulation at the World Intellectual Property Organization (WIPO) will compromise TRIPS flexibilities, especially in relation to the scope of patentability for national patent offices. The International Bureau (i.e. WIPO … Continue reading

Posted in Patent, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WIPO | Leave a comment

Prices of Patented Medicines in India

Source: Economic & Political Weekly | Vol. 53, Issue No. 22, 02 Jun, 2018 by Sharmila Mary Joseph  & James J Nedumpara To Regulate or Not to Regulate? Medicines with valid patents generally enjoy exemption from price regulation in most countries. In India, … Continue reading

Posted in Access to Medecines, Doha Declaration, Patent, Patents, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

US faith-based groups call for no TRIPS-plus in NAFTA

Top leadership from multiple major faith denominations strongly reaffirmed their traditions’ recognition of the human right to health, and insisted that trade agreements including a renegotiated NAFTA should not include terms that extend medicine monopolies. The statement, found here: http://www.usccb.org/issues-and-action/human-life-and-dignity/global-issues/trade/upload/NAFTA-and-International-Public-Health-An-Interfaith-Call-for-Access-to-Medicines.pdfContinue reading

Posted in NAFTA, TRIPS, TRIPS plus, Uncategorized | Leave a comment

Why do new medicines cost so much, and what can we do about it?

  The cost of new drugs is putting increasing pressure on people in both rich and poor countries. We explain why it’s a burning issue by Sarah Boseley Health editor Why does it matter what medicines cost? If you are lucky enough … Continue reading

Posted in Doha Declaration, Patent, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment